-
Pediatrics in Review Jul 2023
Topics: Humans; Poliomyelitis
PubMed: 37391633
DOI: 10.1542/pir.2022-005948 -
Nature Jul 2023
Topics: Humans; Poliomyelitis; Disease Eradication; Global Health; Poliovirus Vaccine, Oral; Poliovirus Vaccine, Inactivated
PubMed: 37316591
DOI: 10.1038/d41586-023-01773-9 -
Tropical Medicine & International... Nov 2023
Topics: Humans; Pakistan; Poliomyelitis; Vaccination; Disease Eradication; Immunization Programs
PubMed: 37775966
DOI: 10.1111/tmi.13935 -
European Journal of Physical and... Apr 2024Poliomyelitis is a global disabling disease affecting 12-20 million of people. Post poliomyelitis syndrome (PPS) may affect up to 80% of polio survivors: increased...
BACKGROUND
Poliomyelitis is a global disabling disease affecting 12-20 million of people. Post poliomyelitis syndrome (PPS) may affect up to 80% of polio survivors: increased muscle weakness, pain, fatigue, functional decline. It relies on aging of an impaired neuro-muscular system with ongoing denervation processes. A late involvement of humoral or cellular pro-inflammatory phenomena is also suspected.
AIM
To assess the dysimmune hypothesis of PPS by comparing lymphocyte subpopulations and humoral immune factors between PPS patients and controls.
DESIGN
Cross-sectional study.
SETTING
Montpellier University Hospital.
POPULATION
Forty-seven PPS and 27 healthy controls.
METHODS
PPS patients and controls were compared on their lymphocyte subpopulations and humoral immune factors (IL-1β, IL-6, IL-8, IL-17, IL-21, IL-22, IL-23, IFN-γ, TNF-α, GM-CSF, RANTES, MCP1, MIP-3a, IL-10, TGF-β, IL4, IL13). Patients were further compared according to their dominant clinical symptoms. Sample size guaranteed a power >90% for all comparisons.
RESULTS
PPS patients and controls were comparable in gender, age and corpulence. Most patients had lower limb motor sequelae (N.=45, 95.7%), a minority had upper limb motor impairment (N.=16, 34.0%). Forty-five were able to walk (94%), 35/45 with technical aids. The median of the two-minute walking test was 110 meters (interquartile range 55; 132). Eighteen (38%) required help in their daily life. Their quality of life was low (SF36). All described an increased muscular weakness, 40 (85%) a general fatigue, and 39 (83%) muscular or joint pain. Blood count, serum electrolytes, T and B lymphocyte subpopulations and cytokines were comparable between patients and controls, except for creatine phospho kinase that was significantly higher in PPS patients. None of these variables differed between the 20/47 patients whose late main symptoms were pain or fatigue, and other patients.
CONCLUSIONS
Our results suggest that PPS is not a dysimmune disease.
CLINICAL REHABILITATION IMPACT
Our results do not sustain immunotherapy for PPS. Our work suggest that PPS may be mostly linked to physiological age-related phenomena in a disabled neuromuscular condition. Thus, our results emphasize the role of prevention and elimination of aggravating factors to avoid late functional worsening, and the importance of rehabilitation programs that should be adapted to patients' specific conditions.
Topics: Humans; Postpoliomyelitis Syndrome; Cross-Sectional Studies; Quality of Life; Poliomyelitis; Pain; Fatigue; Muscle Weakness; Immunologic Factors
PubMed: 38252127
DOI: 10.23736/S1973-9087.23.08158-3 -
Revista Brasileira de Epidemiologia =... 2023To analyze the coverage of MMR and polio vaccines, the temporal trend and spatial dependence, in children up to one year of age in Brazil, between 2011 and 2021.
OBJECTIVE
To analyze the coverage of MMR and polio vaccines, the temporal trend and spatial dependence, in children up to one year of age in Brazil, between 2011 and 2021.
METHODS
Ecological study with secondary data on vaccination coverage rates, made available by the National Immunization Program Information System. Trend analysis was carried out using the joinpoint method, according to geographic regions, estimating the annual percentage change (APC) and its respective confidence interval (95%CI). Choropleth maps of distribution by health region were constructed and, subsequently, the spatial dependence was verified using Moran's statistics.
RESULTS
Between 2011 and 2021, vaccination coverage declined in Brazil, both for MMR (APC: -6.4%; 95%CI -9.0; -3.8) and for poliomyelitis (APC: -4. 5%; 95%CI -5.5; -3.6). There was a decline in coverage of both vaccines in all geographic regions over the years of the study, except in the South and Midwest for the MMR vaccine. Since 2015, few health regions in the country have achieved adequate vaccination coverage (≥95.0% to <120.0%). The North and Northeast health regions showed low-low clusters in the univariate analysis for both immunobiological.
CONCLUSIONS
It is urgent to consider studies like this one for the planning of more effective strategies for immunizing children, especially in areas with higher falls. In this way, barriers to access to immunization can be broken, given Brazil's heterogeneity, and access to reliable information that increases confidence in vaccine efficacy can be expanded.
Topics: Child; Humans; Vaccination Coverage; Brazil; Vaccination; Poliomyelitis; Vaccines; Spatial Analysis
PubMed: 37878834
DOI: 10.1590/1980-549720230047 -
Human Vaccines & Immunotherapeutics Dec 2024DTaP-HBV-IPV-Hib hexavalent vaccine has been used in high-income countries for many years to prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and...
DTaP-HBV-IPV-Hib hexavalent vaccine has been used in high-income countries for many years to prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive Haemophilus influenzae type b disease. Currently, no hexavalent vaccines have been approved for use in China. Evidence of parental acceptance and interest in hexavalent vaccines can help policy makers and manufacturers make decisions about entering the vaccine market and the immunization program in China. We measured parental acceptance and willingness-to-pay (WTP) for a hexavalent vaccine to provide such evidence. We conducted a cross-sectional survey of children's caregivers in 16 vaccination clinics in seven cities in China and obtained information on socio-demographics, knowledge of disease, confidence in vaccines, previous vaccination experience, and acceptance of and WTP for hexavalent vaccine. Multivariate logistic regression was used to determine factors influencing acceptance, and multivariate tobit regression was used to identify factors impacting WTP. Between April 28 and June 30, 2023, a total of 581 parents of children aged 0-6 years participated in the survey; 435 (74.87%, 95% CI:71.3%-78.4%) parents indicated acceptance of hexavalent vaccine. Residence location, parents' education level, experience paying for vaccination, and disease knowledge scores were key factors affecting parents' choices for vaccination. Mean (SD) and median (IQR) willingness to pay for full 4-dose course vaccination were 2266.66 (1177.1) CNY and 2400 (1600-2800) CNY. Children's age ( < .001), parents' education level ( = .024), and perceived price barriers ( < .001) were significantly associated with WTP. Parents have high acceptance and willingness to pay for hexavalent vaccine. The less money parents have to pay out of pocket, the more willing they can be to accept the vaccine. Therefore, acceptance may increase even further if the vaccine is covered by medical insurance, provided free of charge by the government, or if its price is reduced. Our results provide reference for optimizing and adjusting immunization strategies in China.
Topics: Child; Humans; Vaccines, Combined; Cross-Sectional Studies; Haemophilus influenzae type b; China; Diphtheria-Tetanus-Pertussis Vaccine; Hepatitis B Vaccines; Haemophilus Vaccines
PubMed: 38619056
DOI: 10.1080/21645515.2024.2333098 -
Journal of Child Health Care : For... Sep 2023Although all European countries have vaccination policies for children, there are no comprehensive studies of pediatric vaccination programs in Europe. We studied...
Although all European countries have vaccination policies for children, there are no comprehensive studies of pediatric vaccination programs in Europe. We studied vaccination programs for children in Europe. Vaccinations against diphtheria, tetanus, pertussis, poliomyelitis, type b, hepatitis B, measles, mumps, rubella, and influenza existed in 42 countries, against human papilloma virus in 41 countries, and against pneumococcus in 40 countries. In addition, the following vaccinations existed: against tuberculosis (35 countries), hepatitis A (33), meningococcus A, C, W, Y (30), rotavirus and varicella (28 countries each), meningococcus B (24), tick-born encephalitis (22), and meningococcus C (16). Mandatory vaccinations are implemented in 21 countries, mainly against diphtheria, tetanus, pertussis, poliomyelitis, type b, hepatitis B, measles, mumps, rubella, tuberculosis, and pneumococcus. There are significant differences among pediatric vaccination programs in Europe regarding number, schedules, indications, and regulatory frame (recommended or mandatory vaccinations). A consensus-based vaccination program for all children is needed.
Topics: Child; Humans; Tetanus; Mumps; Whooping Cough; Diphtheria; Vaccination; Europe; Measles; Rubella; Poliomyelitis; Hepatitis B
PubMed: 34844456
DOI: 10.1177/13674935211055294 -
Medecine Tropicale Et Sante... Jun 2023It may seem surprising that the Editorial Board of would agree to publish the article "Increasing the efficiency of a mobile EPI strategy using injectable polio vaccine...
It may seem surprising that the Editorial Board of would agree to publish the article "Increasing the efficiency of a mobile EPI strategy using injectable polio vaccine in Africa" 35 years after the work was completed in 1988. I briefly outline the rationale for this decision here.
Topics: Humans; Vaccines, Inactivated; Vaccination; Poliomyelitis; Immunization Programs; Africa
PubMed: 37525674
DOI: 10.48327/mtsi.v3i2.2023.380 -
Disability and Rehabilitation Oct 2023To investigate the prevalence of fibromyalgia(FM) and to show its relations with symptoms, polio-related impairments (PRI), and quality of life (QoL) in persons with...
Coexistence of fibromyalgia and post-polio syndrome in persons with prior poliomyelitis in Turkey: the relations with symptoms, polio-related impairments, and quality of life.
PURPOSE
To investigate the prevalence of fibromyalgia(FM) and to show its relations with symptoms, polio-related impairments (PRI), and quality of life (QoL) in persons with prior paralytic poliomyelitis (PsPP) with and without post-polio syndrome (PPS).
MATERIALS AND METHODS
The study included 74 PsPP under 60 years of age, 60 of whom met the criteria for PPS. Presence and severity of FM were assessed by the American College of Rheumatology (ACR) 1990, 2010, and 2016 criteria, and Fibromyalgia Severity Score. PPS symptoms, PRI, and QoL were evaluated using the Self-Reported Impairments in Persons with Late Effects of Polio Rating Scale, Fatigue Severity Scale, and Nottingham Health Profile. Frequency, comparison, and correlation analyses were performed.
RESULTS
While 15% of PsPP with PPS met the criteria of ACR 1990, 32% of ACR 2010, and 35% of ACR 2016, none of those without PPS met any of the criteria for FM. Severity of PPS symptoms and PRI were significantly higher, and QoL was significantly lower in those with co-existing FM. FM severity was found to be significantly associated with severity of PPS symptoms, PRI and reduced QoL.
CONCLUSIONS
FM frequently coexists in PsPP with PPS and may increase the burden of PPS.Implications for RehabilitationFibromyalgia (FM) is commonly seen in patients with post-polio syndrome (PPS).Co-existing FM may increase the burden of PPS, as it is associated with more severe symptoms, more polio-related impairments, and worse quality of life.Recognition, appropriate referral, and successful management of co-existing FM may allow for reduced symptoms or symptom severity and improved quality of life in persons with PPS.
Topics: Humans; Middle Aged; Postpoliomyelitis Syndrome; Fibromyalgia; Quality of Life; Turkey; Poliomyelitis; Severity of Illness Index
PubMed: 36169616
DOI: 10.1080/09638288.2022.2127931 -
The Pediatric Infectious Disease Journal Jun 2024
Topics: Poliomyelitis; Humans; Disease Eradication; Global Health; Immunization Programs; Poliovirus Vaccines; Poliovirus Vaccine, Oral
PubMed: 38564755
DOI: 10.1097/INF.0000000000004330